This site is intended for patients in Great Britain (England, Scotland and Wales) who have been prescribed PIQRAY®▼ (alpelisib) + fulvestrant.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

How will my treatment be managed and monitored?

There are some tests you will need to have done regularly to monitor your condition. Some, such as scans, will check to see if your breast cancer is responding to treatment or progressing. Others will check for side effects of treatment. For example, there will be particularly regular monitoring for high blood sugar (hyperglycaemia), as this is a very common and serious side effect of this treatment.1

Getting these tests scheduled in can help you:

  • Stick to your treatment plan
  • Know what side effects to expect
  • Find out how your cancer is responding to treatment.

Treatment tracker

Using this treatment tracker will help you know where you are with your Piqray and fulvestrant doses.

Treatment tracker

Download this treatment tracker, fill it out and take it with you to your appointments. This can help make sure you are taking your medicine as prescribed.

Appointments

View our useful tips to help you prepare for your healthcare appointments, in order to get the most out of them.

Click below to find useful tips on managing your healthcare appointments.

Treatment banner image

Read the Piqray® patient brochure for even more about managing your appointments and receiving treatment with Piqray and fulvestrant.

Where would you like to go next? 

Abbreviation

aBC, advanced breast cancer.
 

Reference

  1. PIQRAY® (alpelisib) Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/11684/pil. [Accessed November 2021].

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

UK | January 2022 | 147273